Cutting-edge updates in the diagnosis and treatment of hematological malignancies were discussed by world-leading experts at the Annual Meeting of the American Society of ­Clinical Oncology (ASCO) in Chicago, USA, 2nd–6th June 2023, the European Hematology Association (EHA) congress in Frankfurt, Germany, 8th-11th June 2023, and the 17th International conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, 13th-17th June2023. In this special issue we provide current insights into BTK inhibition and other targeted approaches in chronic lymphocytic leukemia, summarize study results with bispecific antibodies and BTK inhibitors in follicular lymphoma and present outcome improvements in relapsed and untreated marginal zone lymphoma. Moreover, the ASPEN and BRUIN data are highlighted in patients with Waldenström macroglobulinemia. A special focus is drown on elderly patients with diffuse large B-cell lymphoma while finally drawing attention to the promising findings obtained with novel agents targeting BTK and Bcl-2 invarious B-cell malignancies.

Asan additional feature, you will find expert video interviews with Alessandra Tedeschi, Anna Schuh, Paolo Strati and Philipp Staber on different conference highlights on our website.

Access and article directly (English):

1. Preface

2. Current insights into BTK inhibition and other targeted approaches in CLL

3. Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors

4. Outcome improvements in relapsed and untreated marginal zone lymphoma

5. Waldenström macroglobulinemia: findings from ASPEN and BRUIN

6. DLBCL: treatment of elderly patients and relapsed disease

7. Updates on BTK- and Bcl-2–targeted treatment in various B-cell malignancies

8. Full Report (English)

9. Slide Kit (English)